Immunotherapy with gene-modified T cells: limiting side effects provides new challenges.
about
Immune targeting of cancer stem cells in gastrointestinal oncologyMetabolic communication in tumors: a new layer of immunoregulation for immune evasionThe Application of Natural Killer Cell Immunotherapy for the Treatment of CancerImmunotherapy in Multiple Myeloma Using Cancer-Testis AntigensPathways and therapeutic targets in melanomaAdvantages and applications of CAR-expressing natural killer cellsCD19-Chimeric Antigen Receptor T Cells for Treatment of Chronic Lymphocytic Leukaemia and Acute Lymphoblastic LeukaemiaBack to the future! The evolving role of maintenance therapy after hematopoietic stem cell transplantation.Induction of a specific CD8+ T-cell response to cancer/testis antigens by demethylating pre-treatment against osteosarcomaCD8 T cell tolerance to a tumor-associated self-antigen is reversed by CD4 T cells engineered to express the same T cell receptorAdoptive T-cell therapy for cancer in the United kingdom: a review of activity for the British Society of Gene and Cell Therapy annual meeting 2015.CD4(+) and CD8(+) TCRβ repertoires possess different potentials to generate extraordinarily high-avidity T cells.T Cells Engineered With Chimeric Antigen Receptors Targeting NKG2D Ligands Display Lethal Toxicity in Mice.Expression of a dominant T-cell receptor can reduce toxicity and enhance tumor protection of allogeneic T-cell therapy.A role for multiple chimeric antigen receptor-expressing leukocytes in antigen-specific responses to cancer.Genetically engineered donor T cells to optimize graft-versus-tumor effects across MHC barriers.An allogeneic NK cell line engineered to express chimeric antigen receptors: A novel strategy of cellular immunotherapy against cancer.CD8+ T-cell specificity is compromised at a defined MHCI/CD8 affinity threshold.Adoptive immunotherapy with genetically modified lymphocytes in allogeneic stem cell transplantation.Cancer Immunotherapy Using γδT Cells: Dealing with Diversity.Mechanisms of tumor-induced T cell immune suppression and therapeutics to counter those effects.Inclusion of an IgG1-Fc spacer abrogates efficacy of CD19 CAR T cells in a xenograft mouse model.Exploiting cytokines in adoptive T-cell therapy of cancer.Analogue peptides for the immunotherapy of human acute myeloid leukemia.Prospects for adoptive immunotherapy of pancreatic cancer using chimeric antigen receptor-engineered T-cells.NK cell-based cancer immunotherapy: from basic biology to clinical application.Adoptive Cellular Therapy (ACT) for Cancer Treatment.Optimization of T-cell Reactivity by Exploiting TCR Chain Centricity for the Purpose of Safe and Effective Antitumor TCR Gene Therapy.GUCY2C-directed CAR-T cells oppose colorectal cancer metastases without autoimmunity.Development of T cells carrying two complementary chimeric antigen receptors against glypican-3 and asialoglycoprotein receptor 1 for the treatment of hepatocellular carcinoma.
P2860
Q26749015-B1EDA167-18DE-4EBA-BD24-33B5CD8CE50AQ26765256-BE7C77F0-8F8A-4034-957C-F4E3C7ADDAE0Q26774678-AE65788B-88E3-4C71-B0B9-859CCDAF16BEQ26774913-6D7AD55D-4554-4B2E-B4AE-5295FD9A5CE8Q26865736-50C36A93-2D72-4935-961A-1FC6AC43711DQ28080875-2096BADB-2BE9-4B05-9237-429D7BC860CEQ28081600-33A6859E-F4F1-4269-977D-23B0C319503FQ34380489-07C841B7-E137-4C11-B6D5-3FCFF5863991Q34786566-E55665DB-B260-4FCF-ADA8-42F0E6E01BEBQ34981606-87CBB8AF-9A52-4FA8-9770-23649502EA09Q35641721-29F797D0-DB84-4D4B-B826-F542244D5D1AQ36748257-9DEE9E5C-82B1-4A57-B32E-C1DAF069685DQ36757142-32EDD78F-73A1-4FE5-862A-5C7A2B5DAEA3Q37216330-8B687256-980E-4544-B746-CB036C020DFAQ37376346-E7C5A435-DEF8-4C3B-A083-2AF2CFAB3A75Q37416883-BF63EC5C-0D49-47FC-AC10-336126D227C1Q37488222-A762968E-0FAA-437F-BD3D-686CE24E6B50Q37560213-528E99EF-5E0F-47F8-A59C-18BB08D122DAQ38170501-88131023-569C-4A23-A444-ED6F8365802DQ38283536-FE05FA05-F2B8-4F98-9502-17F417D67DC0Q38336989-BDED6F08-904A-402B-9D20-4E55DFDB9B07Q38445486-341A89C0-B511-4201-A854-A670D5CEC784Q38525044-4F1491C8-3BCE-4412-9887-1CADDB77CA13Q38599586-989B1BF8-D080-4EB5-BB31-B732A64AB711Q38608986-F85D446A-BF7A-491E-B223-3587EF3BDDB7Q38640489-EF7D0985-2C15-4D8D-B0C9-31DF222510CDQ38848219-82F04B05-5850-4DF1-96DF-A19D88BD5A4FQ41257879-C192B1A7-3A0B-4479-B03E-838E1E3BE3AFQ41625041-69C009C8-4B6A-46A7-9529-798D3A53A631Q50035377-031C1C78-2FCF-46E0-8385-F2BCF94296BF
P2860
Immunotherapy with gene-modified T cells: limiting side effects provides new challenges.
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Immunotherapy with gene-modified T cells: limiting side effects provides new challenges.
@en
type
label
Immunotherapy with gene-modified T cells: limiting side effects provides new challenges.
@en
prefLabel
Immunotherapy with gene-modified T cells: limiting side effects provides new challenges.
@en
P2860
P356
P1433
P1476
Immunotherapy with gene-modified T cells: limiting side effects provides new challenges
@en
P2093
H J Stauss
P2860
P2888
P304
P356
10.1038/GT.2013.34
P577
2013-06-27T00:00:00Z